Clinical trials: Urinary Bladder Diseases\Urologic Diseases
Breast Cancer, Bladder Cancer
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of…
- Trial name
- NCT02695121
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 2,133,575 people
- Sponsor
- AstraZeneca
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
- Trial name
- NCT01286454
- Testing
- fesoterodine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overactive Bladder
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only.
- Conditions
- Obesity, Overactive Bladder, Incontinence
- Trial name
- NCT00932022
- Testing
- Trospium Chloride, Extended Release (XR)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Urothelial Cancer
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
- Trial name
- NCT07106762
- Testing
- Iza-bren, Cisplatin, Gemcitabine
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus…
- Trial name
- NCT00461591
- Testing
- Apaziquone, TURBT
- Where
- 74 sites in United States
- Volunteers
- 802 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Overactive Bladder (OAB)
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.
- Trial name
- NCT03602508
- Testing
- mirabegron, solifenacin, darifenacin
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 5,589 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Cystitis, Interstitial, Painful Bladder Syndrome
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT02411110
- Testing
- LiRIS®
- Where
- 34 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Allergan
Overactive Bladder
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
This is a two-part study. Part 1 is designed to find the best modified release formulation of GW423753; Part 2 is designed to use the selected formulation(s) from Part 1 to find out if food affects the way the medication is…
- Trial name
- NCT00427596
- Testing
- Solabegron
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms, Overactive Bladder
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder…
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT02715024
- Testing
- Tamsulosin, Solifenacin
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Taiwan, Inc.
NMIBC, High Risk NMIBC
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
This is a first-in-human, multicenter, Phase 1/1b, 3-part, double-blind study of ZH9 in patients with recurrent NMIBC who are eligible for intravesical therapy.
- Conditions
- NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
- Trial name
- PARADIGM-1 (NCT06181266)
- Testing
- ZH9
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Prokarium Ltd
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Overactive Bladder
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory…
- Trial name
- NCT01178827
- Testing
- trospium chloride, oxybutynin IR
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Allergan
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Overactive Bladder
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive bladder syndrome.
- Trial name
- NCT00138723
- Testing
- SPM 907
- Sponsor
- Pfizer
Bladder Cancer
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy.
- Trial name
- TroFuse-031 (NCT07419295)
- Testing
- Sacituzumab tirumotecan, Vinflunine, Docetaxel
- Where
- 111 sites in United States, Argentina and 15 more
- Volunteers
- 590 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
This is a phase II, single center open label to determine safety, dose tolerance, PK and PD of the recommended Phase 2 dose (RP2D) of CPX-POM administered in patients with any newly diagnosed or recurrent bladder tumors.
- Trial name
- NCT04525131
- Testing
- CPX-POM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- CicloMed LLC
Overactive Bladder With Urge Urinary Incontinence
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder…
- Trial name
- NCT04211831
- Testing
- URO-902
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Urovant Sciences GmbH
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Benign Prostatic Hyperplasia
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Trial name
- NCT01438775
- Testing
- NX-1207
- Where
- 28 sites in United States
- Volunteers
- 192 people
- Sponsor
- Nymox Corporation